American Society of Hematology Annual Meeting & Exposition

The American Society of Hematology (ASH) will host its 60th annual meeting December 1-4, 2018, in San Diego, California. The meeting will bring together more than 25,000 hematology professionals from various subspecialties, including oncology. Sign up for our daily email blasts on our registration page, and check back here during the conference for full coverage.
January 22, 2019
Despite their growing prevalence, there is still a lack of biosimilar education amongst stakeholders, said Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.
January 10, 2019
The biggest barrier to positive clinical outcomes in multiple myeloma is access, explained Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.
January 08, 2019
Jennifer R. Brown, MD, PhD, director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, discusses how genomic sequencing plays a role in determining prognosis and treatment for patients with chronic lymphocytic leukemia (CLL).
January 07, 2019
Theresa Keegan, PhD, MS, associate professor, hematology and oncology, University of California at Davis Comprehensive Cancer Center, outlines barriers and facilitators to clinical trial participation among adolescents and young adults (AYAs).
January 06, 2019
As treatment moves to pill-based regimens in chronic lymphocytic leukemia (CLL), the cost for patients is increasing, explained Jeff Sharman, MD, medical oncologist, Willamette Valley Cancer Institute and Research Center; medical director, The US Oncology Network.
December 18, 2018
During the 60th American Society of Hematology Annual Meeting & Exposition held December 1-4 in San Diego, California, Norman Sharpless, MD, director, National Cancer Institute (NCI), brought attention to several advances made in hematologic malignancies over the past year and highlighted 4 areas of focus going forward.
December 03, 2018
Although there haven't been as many new drug approvals for multiple myeloma as there were last year, there are many new agents entering the market and exciting new discoveries, said Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.
December 03, 2018
Patients with Down syndrome are at an increased risk for developing leukemia, but how much of an increased risk depends on age, explained Irene Roberts, MD, professor of pediatric hematology, MRC molecular hematology unit and pediatrics, MRC Weatherall Institute of Molecular Medicine.
December 03, 2018
Ibrutinib combined with obinutuzumab had better progression-free survival (PFS) at 30 months than the standard chemoimmunotherapy regimen, chlorambucil plus obinutuzumab, regardless of high-risk genomic features in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who had never been treated.
December 03, 2018
While several associations between constitutional syndromes, such as Down syndrome, and predisposition to cancers have been recognized, recommendations for surveillance or clear association between the 2 are lacking.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
×

Sign In

Not a member? Sign up now!